Products:

LBS-Neurons - Layton Bioscience, Inc. has developed and currently produces clinical grade human neuronal cells for potential therapeutic use in a variety of central nervous system and other neurological disorders.

Nicotinic Acetylcholine Receptor Antagonists - In September 1997, Layton secured from the University of South Florida an exclusive, worldwide license for the use of nicotinic acetylcholine receptor antagonists for the treatment of neuropsychiatric disorders.

In Situ Transcription/aRNA Amplification - Layton BioScience's position in this field was developed and patented by one of its founding scientists, Dr. James Eberwine, first at Stanford University and later at the University of Pennsylvania.

Methanesulfonyl Fluoride (MSF) - In May 1998, Layton obtained an exclusive license agreement with the University of Texas at El Paso (UTEP) for a patent covering the use of methanesulfonyl fluoride (MSF) for the treatment of dementia of the Alzheimer's type.